Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Louise A. Brinton is active.

Publication


Featured researches published by Louise A. Brinton.


Nature Genetics | 2007

A common coding variant in CASP8 is associated with breast cancer risk

Angela Cox; Alison M. Dunning; Montserrat Garcia-Closas; Sabapathy P. Balasubramanian; Malcolm Reed; Karen A. Pooley; Serena Scollen; Caroline Baynes; Bruce A.J. Ponder; Stephen J. Chanock; Jolanta Lissowska; Louise A. Brinton; Beata Peplonska; Melissa C. Southey; John L. Hopper; Margaret McCredie; Graham G. Giles; Olivia Fletcher; Nichola Johnson; Isabel dos Santos Silva; Lorna Gibson; Stig E. Bojesen; Børge G. Nordestgaard; Christen K. Axelsson; Diana Torres; Ute Hamann; Christina Justenhoven; Hiltrud Brauch; Jenny Chang-Claude; Silke Kropp

The Breast Cancer Association Consortium (BCAC) has been established to conduct combined case-control analyses with augmented statistical power to try to confirm putative genetic associations with breast cancer. We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 −202 C → A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3′ UTR A → G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913). We included data from 9–15 studies, comprising 11,391–18,290 cases and 14,753–22,670 controls. We found evidence of an association with breast cancer for CASP8 D302H (with odds ratios (OR) of 0.89 (95% confidence interval (c.i.): 0.85–0.94) and 0.74 (95% c.i.: 0.62–0.87) for heterozygotes and rare homozygotes, respectively, compared with common homozygotes; Ptrend = 1.1 × 10−7) and weaker evidence for TGFB1 L10P (OR = 1.07 (95% c.i.: 1.02–1.13) and 1.16 (95% c.i.: 1.08–1.25), respectively; Ptrend = 2.8 × 10−5). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.NOTE: In the version of this article initially published, there was an error that affected the calculations of the odds ratios, confidence intervals, between-study heterogeneity, trend test and test for association for SNP ICAM5 V301I in Table 1 (ICAM5 V301I); genotype counts in Supplementary Table 2 (ICAM5; ICR_FBCS and Kuopio studies) and minor allele frequencies, trend test and odds ratios for heterozygotes and rare homozygotes in Supplementary Table 3 (ICAM5; ICR_FBCS and Kuopio studies). The errors in Table 1 have been corrected in the PDF version of the article. The errors in supplementary information have been corrected online.


Nature Genetics | 2009

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).

Gilles Thomas; Kevin B. Jacobs; Peter Kraft; Meredith Yeager; Sholom Wacholder; David G. Cox; Susan E. Hankinson; Amy Hutchinson; Zhaoming Wang; Kai Yu; Nilanjan Chatterjee; Montserrat Garcia-Closas; Jesus Gonzalez-Bosquet; Ludmila Prokunina-Olsson; Nick Orr; Walter C. Willett; Graham A. Colditz; Regina G. Ziegler; Christine D. Berg; Saundra S. Buys; Catherine A. McCarty; Heather Spencer Feigelson; Eugenia E. Calle; Michael J. Thun; Ryan Diver; Ross L. Prentice; Rebecca D. Jackson; Charles Kooperberg; Rowan T. Chlebowski; Jolanta Lissowska

We conducted a three-stage genome-wide association study (GWAS) of breast cancer in 9,770 cases and 10,799 controls in the Cancer Genetic Markers of Susceptibility (CGEMS) initiative. In stage 1, we genotyped 528,173 SNPs in 1,145 cases of invasive breast cancer and 1,142 controls. In stage 2, we analyzed 24,909 top SNPs in 4,547 cases and 4,434 controls. In stage 3, we investigated 21 loci in 4,078 cases and 5,223 controls. Two new loci achieved genome-wide significance. A pericentromeric SNP on chromosome 1p11.2 (rs11249433; P = 6.74 × 10−10 adjusted genotype test, 2 degrees of freedom) resides in a large linkage disequilibrium block neighboring NOTCH2 and FCGR1B; this signal was stronger for estrogen-receptor–positive tumors. A second SNP on chromosome 14q24.1 (rs999737; P = 1.74 × 10−7) localizes to RAD51L1, a gene in the homologous recombination DNA repair pathway. We also confirmed associations with loci on chromosomes 2q35, 5p12, 5q11.2, 8q24, 10q26 and 16q12.1.


American Journal of Obstetrics and Gynecology | 1997

Cancer risk after a hospital discharge diagnosis of endometriosis

Louise A. Brinton; Gloria Gridley; Ingemar Persson; John A. Baron; Agneta Bergqvist

OBJECTIVES Our goal was to determine the risk of cancer after hospitalization for endometriosis. STUDY DESIGN Records of 20,686 women hospitalized with endometriosis during the period 1969 to 1983, as identified through the nationwide Swedish Inpatient Register, were linked against the National Swedish Cancer Registry through 1989 to identify all subsequent diagnoses of cancer. The study subjects were followed up for a mean of 11.4 years, with the cohort contributing 216,851 woman years of follow-up. Standardized incidence ratios were computed by the use of age- and period-specific incidence rates derived from the Swedish population. Because of the high proportion of subjects with gynecologic operations (55.6%), evaluation of the risk of gynecologic cancers involved truncation of person years at the time of any such operation. RESULTS The overall cancer risk was 1.2 (95% confidence interval 1.1 to 1.3). Significant excesses were observed for breast cancer (standardized incidence ratio = 1.3, 95% confidence interval 1.1 to 1.4), ovarian cancer (1.9, 1.3 to 2.8), and hematopoietic malignancies (1.4, 1.0 to 1.8); this latter excess was largely driven by an excess risk of non-Hodgkins lymphoma (1.8, 1.2 to 2.6). The risk of ovarian cancer was particularly elevated among subjects with a long-standing history of ovarian endometriosis (4.2, 2.0 to 7.7). Cervical cancer risk was slightly reduced (0.7, 0.4 to 1.3) whereas no association was observed for cancer of the endometrium (1.1, 0.6 to 1.9). CONCLUSIONS These findings suggest that further attention be given to the risk of breast, ovarian and hematopoietic cancers among women with endometriosis and to exploring possible hormonal and immunologic reasons for the excess risks.


The New England Journal of Medicine | 2010

Performance of common genetic variants in breast-cancer risk models.

Sholom Wacholder; Patricia Hartge; Ross L. Prentice; Montserrat Garcia-Closas; Heather Spencer Feigelson; W. Ryan Diver; Michael J. Thun; David G. Cox; Susan E. Hankinson; Peter Kraft; Bernard Rosner; Christine D. Berg; Louise A. Brinton; Jolanta Lissowska; Mark E. Sherman; Rowan T. Chlebowski; Charles Kooperberg; Rebecca D. Jackson; Dennis W. Buckman; Peter Hui; Ruth M. Pfeiffer; Kevin B. Jacobs; Gilles Thomas; Robert N. Hoover; Mitchell H. Gail; Stephen J. Chanock; David J. Hunter

BACKGROUND Genomewide association studies have identified multiple genetic variants associated with breast cancer. The extent to which these variants add to existing risk-assessment models is unknown. METHODS We used information on traditional risk factors and 10 common genetic variants associated with breast cancer in 5590 case subjects and 5998 control subjects, 50 to 79 years of age, from four U.S. cohort studies and one case-control study from Poland to fit models of the absolute risk of breast cancer. With the use of receiver-operating-characteristic curve analysis, we calculated the area under the curve (AUC) as a measure of discrimination. By definition, random classification of case and control subjects provides an AUC of 50%; perfect classification provides an AUC of 100%. We calculated the fraction of case subjects in quintiles of estimated absolute risk after the addition of genetic variants to the traditional risk model. RESULTS The AUC for a risk model with age, study and entry year, and four traditional risk factors was 58.0%; with the addition of 10 genetic variants, the AUC was 61.8%. About half the case subjects (47.2%) were in the same quintile of risk as in a model without genetic variants; 32.5% were in a higher quintile, and 20.4% were in a lower quintile. CONCLUSIONS The inclusion of newly discovered genetic factors modestly improved the performance of risk models for breast cancer. The level of predicted breast-cancer risk among most women changed little after the addition of currently available genetic information.


Cancer Epidemiology, Biomarkers & Prevention | 2007

Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study

Xiaohong R. Yang; Mark E. Sherman; David L. Rimm; Jolanta Lissowska; Louise A. Brinton; Beata Peplonska; Stephen M. Hewitt; William F. Anderson; Neonila Szeszenia-Dąbrowska; Alicja Bardin-Mikolajczak; Richard W. Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanisław Lukaszek; Radzisaw Kordek; Montserrat Garcia-Closas

Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor α, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95% confidence intervals. We observed that compared with the predominant luminal A tumors (69%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8%) and basal-like (12%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; Pheterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; Pheterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(3):439–43)


American Journal of Obstetrics and Gynecology | 1992

Reproductive, menstrual, and medical risk factors for endometrial cancer : results from a case-control study

Louise A. Brinton; Michael L. Berman; Rodrigue Mortel; Leo B. Twiggs; Rolland J. Barrett; George D. Wilbanks; Linda Lannom; Robert N. Hoover

OBJECTIVE Our objective was to evaluate the risk for endometrial cancer in relation to reproductive, menstrual, and medical factors. STUDY DESIGN A case-control study of 405 endometrial cancer cases and 297 population controls in five areas of the United States enabled risk to be evaluated. RESULTS A major risk factor was the absence of a prior pregnancy (relative risk 2.8, 95% confidence interval 1.7 to 4.6). The protective effect of pregnancy appeared to reflect the influence of term births, because spontaneous and induced abortions were unrelated to risk. Among nulliparous women infertility was a significant risk factor, with women having sought medical advice having nearly eight times the risk of those without difficulty conceiving. After adjustment for other reproductive characteristics, age at first birth and duration of breast-feeding were not related to risk. CONCLUSIONS Elevated risks were found for subjects reporting early ages at menarche (relative risk 2.4 for ages < 12 vs > or = 15) and longer days of flow (relative risk 1.9 for > or = 7 vs < 4 days), but there was no relationship with late ages at natural menopause. Height was not associated with risk, but there was a significant relation to weight, with the risk for 200 versus < 125 pounds being 7.2 (95% confidence interval 3.9 to 13.3). After adjustment for weight and other factors, histories of hypertension and gallbladder disease were not significantly related to risk, but an effect of diabetes persisted (relative risk 2.0, 95% confidence interval 1.1 to 3.6). Hirsutism developing at older ages was also significantly related (relative risk 2.0, 95% confidence interval 1.2 to 3.4).


International Journal of Cancer | 2000

Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study

Yu-Tang Gao; Xiao-Ou Shu; Qi Dai; John D. Potter; Louise A. Brinton; Wan-Qing Wen; Thomas A. Sellers; Lawrence H. Kushi; Zhi-Xian Ruan; Roberd M. Bostick; Fan Jin; Wei Zheng

The incidence of breast cancer among women in Shanghai, a traditionally low‐risk population, has increased substantially over the past 20 years. To evaluate the association of menstrual and reproductive factors with breast cancer risk and the influence of these factors on the temporal trend of breast cancer incidence, we analyzed data from the Shanghai Breast Cancer Study, a population‐based case‐control study of breast cancer recently completed among Chinese women in urban Shanghai. In‐person interviews were completed for 1,459 women newly diagnosed with breast cancer between ages 25 and 64 and for 1,556 controls frequency‐matched to cases by age. Unconditional logistic regression was employed to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) related to menstrual and reproductive factors. Earlier menarcheal age, nulliparity, and later age at first live birth were associated with increased risk of breast cancer among both pre‐ and post‐menopausal women, while never having breast‐fed and later age at menopause were associated with elevated risk only among post‐menopausal women. Among controls, 32% of younger women (≤40 years) and 24% of older women (>40 years) reported starting menarche at age of 13 or younger, and this factor contributed to 44% of cases diagnosed among younger women and 26% to 28% of cases in older women. Older age at first live birth or at menopause explained a considerable portion of cases diagnosed in older, but not younger, women. Our study suggests that the changes in menstrual and reproductive patterns among women in Shanghai have contributed to the recent increase in breast cancer incidence, particularly among younger women. Int. J. Cancer 87:295–300, 2000.


Cancer | 1988

A population-based case-control study of childhood leukemia in shanghai

Xiao-Ou Shu; Yu-Tang Gao; Ji Tao Tu; Wei Zheng; Louise A. Brinton; Martha S. Linet; Joseph F. Fraumeni

A population‐based case‐control interview study of 309 childhood leukemia cases and 618 healthy population control children was conducted in urban Shanghai, China. Like some studies in other countries, excess risks for both acute lymphocytic leukemia (ALL) and acute nonlymphocytic leukemia (ANLL) were associated with intrauterine and paternal preconception diagnostic x‐ray exposure, and with maternal employment in the chemical and agricultural industries during pregnancy. ANLL was linked to maternal occupational exposure to benzene during pregnancy, whereas both ALL and ANLL were significantly associated with maternal exposure to gasoline and the patients prior use of chloramphenicol. New findings, previously unsuspected, included an association of ANLL with younger maternal age at menarche (odds ratio [OR] = 4.3; 95% confidence interval (CI) = 1.3–13.9); a protective effect for long‐term (>1 year) use of cod liver oil containing vitamins A and D for both ALL (OR = 0.4; 95% CI = 0.2–0.9) and ANLL (OR = 0.3; 95% CI = 0.1–1.0); and excess risks of ANLL among children whose mothers were employed in metal refining and processing (OR = 4.6; 95% CI = 1.3–17.2) and of ALL associated with maternal occupational exposure to pesticides (OR = 3.5; 95% CI = 1.1–11.2). No relationships were found with late maternal age, certain congenital disorders, or familial occurrence, which have been related to childhood leukemia in other studies. In contrast with other reports, an excess of leukemia, primarily ANLL, occurred among second or later‐born rather than firstborn children.


Journal of Chronic Diseases | 1987

Factors influencing the age at natural menopause.

Janet L. Stanford; Patricia Hartge; Louise A. Brinton; Robert N. Hoover; Ron Brookmeyer

To examine sociodemographic, menstrual, reproductive, and other factors which may influence the age at natural menopause, the authors analyzed data from a large series of women participating in a nationwide breast cancer screening program conducted between 1973 and 1980. Standard life table techniques permitted assessment of factors suspected of varying the time to menstrual cessation among 983 premenopausal women, 1091 surgically menopausal women, and 1423 naturally menopausal women. The median age at natural menopause was 51.1 years. Multivariate analysis indicated that parity, irregularity of menstrual cycles before age 25 or first livebirth, and high socioeconomic status were significantly related to menopausal age. These data provide evidence for the hypothesis that certain environmental and hormonal factors which affect ovulation during reproductive years may ultimately postpone the menopause.


Journal of Clinical Oncology | 2013

Type I and II Endometrial Cancers: Have They Different Risk Factors?

Veronica Wendy Setiawan; Hannah P. Yang; Malcolm C. Pike; Susan E. McCann; Herbert Yu; Yong Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S. Weiss; Penelope M. Webb; Piet A. van den Brandt; Koen van de Vijver; Pamela J. Thompson; Brian L. Strom; Amanda B. Spurdle; Robert A. Soslow; Xiao-Ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E. Rohan; Kim Robien; Harvey A. Risch; Fulvio Ricceri; Timothy R. Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H. Olson; Kirsten B. Moysich

PURPOSE Endometrial cancers have long been divided into estrogen-dependent type I and the less common clinically aggressive estrogen-independent type II. Little is known about risk factors for type II tumors because most studies lack sufficient cases to study these much less common tumors separately. We examined whether so-called classical endometrial cancer risk factors also influence the risk of type II tumors. PATIENTS AND METHODS Individual-level data from 10 cohort and 14 case-control studies from the Epidemiology of Endometrial Cancer Consortium were pooled. A total of 14,069 endometrial cancer cases and 35,312 controls were included. We classified endometrioid (n = 7,246), adenocarcinoma not otherwise specified (n = 4,830), and adenocarcinoma with squamous differentiation (n = 777) as type I tumors and serous (n = 508) and mixed cell (n = 346) as type II tumors. RESULTS Parity, oral contraceptive use, cigarette smoking, age at menarche, and diabetes were associated with type I and type II tumors to similar extents. Body mass index, however, had a greater effect on type I tumors than on type II tumors: odds ratio (OR) per 2 kg/m(2) increase was 1.20 (95% CI, 1.19 to 1.21) for type I and 1.12 (95% CI, 1.09 to 1.14) for type II tumors (P heterogeneity < .0001). Risk factor patterns for high-grade endometrioid tumors and type II tumors were similar. CONCLUSION The results of this pooled analysis suggest that the two endometrial cancer types share many common etiologic factors. The etiology of type II tumors may, therefore, not be completely estrogen independent, as previously believed.

Collaboration


Dive into the Louise A. Brinton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jolanta Lissowska

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Robert N. Hoover

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Ruth M. Pfeiffer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gretchen L. Gierach

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Roni T. Falk

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

James V. Lacey

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Beata Peplonska

Nofer Institute of Occupational Medicine

View shared research outputs
Top Co-Authors

Avatar

Nicolas Wentzensen

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge